Recombinant Adeno-Vaccine Expressing Enterovirus 71-Like Particles against Hand, Foot, and Mouth Disease

PLoS Neglected Tropical Diseases

Volumn 9, Issue 4, 2015, Pages

  Tsou, Yueh Liang ^a,b   Lin, Yi Wen ^a   Shao, Hsiao Yun ^a,b   Yu, Shu Ling ^a   Wu, Shang Rung ^c   Lin, Hsiao Yu ^a   Liu, Chia Chyi ^a   Huang, Chieh ^a   Chong, Pele ^a,d   Chow, Yen Hung ^a,d  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AD EVVLP VACCINE; AD LACZ VACCINE; ADENOVIRUS VECTOR; FORMALIN INACTIVATED EV71 VACCINE; GAMMA INTERFERON; INACTIVATED VIRUS VACCINE; INTERLEUKIN 17; INTERLEUKIN 4; PLASMID DNA; RNA; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE; ANTISERUM; CAPSID PROTEIN; IL17A PROTEIN, HUMAN; INACTIVATED VACCINE; INTERLEUKIN 13; NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE; VIRUS VACCINE;

ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; COXSACKIE VIRUS INFECTION; ENTEROVIRUS 71; ENTEROVIRUS INFECTION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; HAND FOOT AND MOUTH DISEASE; ISOLATION AND PURIFICATION; MOUSE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); REAL TIME POLYMERASE CHAIN REACTION; TH1 TH2 BALANCE; TRANSMISSION ELECTRON MICROSCOPY; VIRUS LOAD; WESTERN BLOTTING; ANIMAL; ENTEROVIRUS A; FEMALE; GENETIC ENGINEERING; HAND, FOOT AND MOUTH DISEASE; IMMUNOLOGY; TRANSGENIC MOUSE; VIROLOGY;

ANIMALS; ANTIBODIES, NEUTRALIZING; CAPSID PROTEINS; ENTEROVIRUS A, HUMAN; FEMALE; GENETIC ENGINEERING; HAND, FOOT AND MOUTH DISEASE; IMMUNE SERA; INTERLEUKIN-13; INTERLEUKIN-17; INTERLEUKIN-4; MICE; MICE, TRANSGENIC; VACCINES, INACTIVATED; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 84928910836     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0003692     Document Type: Article

References (57)

1. Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, Tsai SF, et al. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med. 1999;341: 929–935. 10498487
2. Wang SM, Liu CC, Tseng HW, Wang JR, Huang CC, Chen YJ, et al. Clinical spectrum of enterovirus 71 infection in children in southern Taiwan, with an emphasis on neurological complications. Clin Infect Dis. 1999;29: 184–190. 10433583
3. Liu CC, Tseng HW, Wang SM, Wang JR, Su IJ, An outbreak of enterovirus 71 infection in Taiwan, 1998: epidemiologic and clinical manifestations. J Clin Virol. 2000;17: 23–30. 10814935
4. Perez-Velez CM, Anderson MS, Robinson CC, McFarland EJ, Nix WA, Pallansch MA, et al. Outbreak of neurologic enterovirus type 71 disease: a diagnostic challenge. Clin Infect Dis. 2007;45: 950–957. 17879907
5. Huang CC, Liu CC, Chang YC, Chen CY, Wang ST, Yeh TF, Neurologic complications in children with enterovirus 71 infection. N Engl J Med. 1999;341: 936–942. 10498488
6. AbuBakar S, Chee HY, Al-Kobaisi MF, Xiaoshan J, Chua KB, Lam SK, Identification of enterovirus 71 isolates from an outbreak of hand, foot and mouth disease (HFMD) with fatal cases of encephalomyelitis in Malaysia. Virus Res. 1999;61: 1–9. 10426204
7. Lin KH, Hwang KP, Ke GM, Wang CF, Ke LY, Hsu YT, et al. Evolution of EV71 genogroup in Taiwan from 1998 to 2005: an emerging of subgenogroup C4 of EV71. J Med Virol. 2006;78: 254–262. 16372302
8. Lu CH, Huang SW, Lai YL, Lin CP, Shih CH, Huang CC, et al. On the relationship between the protein structure and protein dynamics. Proteins. 2008;72: 625–634. doi: 10.1002/prot.21954 18247347
9. Melnick JL, Schmidt NJ, Mirkovic RR, Chumakov MP, Lavrova IK, Voroshilova MK, Identification of Bulgarian strain 258 of enterovirus 71. Intervirology. 1980;12: 297–302. 6244233
10. Nagy G, Takatsy S, Kukan E, Mihaly I, Domok I, Virological diagnosis of enterovirus type 71 infections: experiences gained during an epidemic of acute CNS diseases in Hungary in 1978. Arch Virol. 1982;71: 217–227. 6285858
11. Wu TN, Tsai SF, Li SF, Lee TF, Huang TM, Wang ML, et al. Sentinel surveillance for enterovirus 71, Taiwan, 1998. Emerg Infect Dis. 1999;5: 458–460. 10341187
12. McMinn PC, An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev. 2002;26: 91–107. 12007645
13. Wang X, Peng W, Ren J, Hu Z, Xu J, Lou Z, et al. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol. 2012;19: 424–429. doi: 10.1038/nsmb.2255 22388738
14. Yamayoshi S, Yamashita Y, Li J, Hanagata N, Minowa T, Takemura T, et al. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med. 2009;15: 798–801. doi: 10.1038/nm.1992 19543282
15. Nishimura Y, Shimojima M, Tano Y, Miyamura T, Wakita T, Shimizu H, Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat Med. 2009;15: 794–797. doi: 10.1038/nm.1961 19543284
16. Lin YW, Yu SL, Shao HY, Lin HY, Liu CC, Hsiao KN, et al. Human SCARB2 transgenic mice as an infectious animal model for enterovirus 71. PLoS One. 2013;8: e57591. doi: 10.1371/journal.pone.0057591 23451246
17. Fujii K, Nagata N, Sato Y, Ong KC, Wong KT, Yamayoshi S, et al. Transgenic mouse model for the study of enterovirus 71 neuropathogenesis. Proc Natl Acad Sci U S A. 2013;110: 14753–14758. doi: 10.1073/pnas.1217563110 23959904
18. Chang HW, Liu CC, Lin MH, Ho HM, Yang YT, Chow YH, et al. Generation of murine monoclonal antibodies which cross-neutralize human enterovirus genogroup B isolates. J Virol Methods. 2011;173: 189–195. doi: 10.1016/j.jviromet.2011.02.003 21315763
19. Chang HW, Lin YW, Ho HM, Lin MH, Liu CC, Shao HY, et al. Protective efficacy of VP1-specific neutralizing antibody associated with a reduction of viral load and pro-inflammatory cytokines in human SCARB2-transgenic mice. PLoS One. 2013;8: e69858. doi: 10.1371/journal.pone.0069858 23936115
20. Chang JY, Chang CP, Tsai HH, Lee CD, Lian WC, Ih Jen S, et al. Selection and characterization of vaccine strain for Enterovirus 71 vaccine development. Vaccine. 2012;30: 703–711. doi: 10.1016/j.vaccine.2011.11.087 22142585
21. Chou AH, Liu CC, Chang JY, Jiang R, Hsieh YC, Tsao A, et al. Formalin-Inactivated EV71 Vaccine Candidate Induced Cross-Neutralizing Antibody against Subgenotypes B1, B4, B5 and C4A in Adult Volunteers. PLoS One. 2013;8: e79783. doi: 10.1371/journal.pone.0079783 24278177
22. Shao HY, Yu SL, Sia C, Chen Y, Chitra E, Chen IH, et al. Immunogenic properties of RSV-B1 fusion (F) protein gene-encoding recombinant adenoviruses. Vaccine. 2009;27: 5460–5471. doi: 10.1016/j.vaccine.2009.07.004 19622401
23. Harro C, Sun X, Stek JE, Leavitt RY, Mehrotra DV, Wang F, et al. Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults. Clinical and vaccine immunology: CVI. 2009;16: 1285–1292. doi: 10.1128/CVI.00144-09 19605598
24. Xiang ZQ, Gao GP, Reyes-Sandoval A, Li Y, Wilson JM, Ertl HC, Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. J Virol. 2003;77: 10780–10789. 14512528
25. McCoy K, Tatsis N, Korioth-Schmitz B, Lasaro MO, Hensley SE, Lin SW, et al. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. J Virol. 2007;81: 6594–6604. 17428852
26. Wang YF, Chou CT, Lei HY, Liu CC, Wang SM, Yan JJ, et al. A mouse-adapted enterovirus 71 strain causes neurological disease in mice after oral infection. J Virol. 2004;78: 7916–7924. 15254164
27. Wu CN, Lin YC, Fann C, Liao NS, Shih SR, Ho MS, Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine. 2001;20: 895–904. 11738755
28. Khong WX, Yan B, Yeo H, Tan EL, Lee JJ, Ng JK, et al. A non mouse-adapted Enterovirus 71 (EV71) strain exhibits neurotropism causing neurological manifestations in a novel mouse model of EV71 infection. J Virol. 2012.
29. Wu SC, Liu CC, Lian WC, Optimization of microcarrier cell culture process for the inactivated enterovirus type 71 vaccine development. Vaccine. 2004;22: 3858–3864. 15364432
30. Liu CC, Lian WC, Butler M, Wu SC, High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero cell culture. Vaccine. 2007;25: 19–24. 16919374
31. Lin YW, Lin HY, Tsou YL, Chitra E, Hsiao KN, Shao HY, et al. Human SCARB2-mediated entry and endocytosis of EV71. PLoS One. 2012;7: e30507. doi: 10.1371/journal.pone.0030507 22272359
32. Liu CC, Chou AH, Lien SP, Lin HY, Liu SJ, Chang JY, et al. Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine. 2011;29: 4362–4372. doi: 10.1016/j.vaccine.2011.04.010 21501643
33. Mizuguchi H, Kay MA, Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum Gene Ther. 1998;9: 2577–2583. 9853524
34. Bradford MM, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical biochemistry. 1976;72: 248–254. 942051
35. Reed LJ MH, A simple method of estimating 50 percent end-points. Am J Hyg. 1938;27: 493–497.
36. Fundamental Virology. Fourth Edition ed.: Lippincott Williams and Wilkins; 2001.
37. Liu CC, Guo MS, Lin FH, Hsiao KN, Chang KH, Chou AH, et al. Purification and characterization of enterovirus 71 viral particles produced from vero cells grown in a serum-free microcarrier bioreactor system. PLoS One. 2011;6: e20005. doi: 10.1371/journal.pone.0020005 21603631
38. Liu CC, Chow YH, Chong P, Klein M. Prospect and challenges for the development of multivalent vaccines against hand, foot and mouth diseases. Vaccine. 2014 DOI: doi: 10.1016/j.vaccine.2014.08.064
39. Yang KD, Yang MY, Li CC, Lin SF, Chong MC, Wang CL, et al. Altered cellular but not humoral reactions in children with complicated enterovirus 71 infections in Taiwan. J Infect Dis. 2001;183: 850–856. 11237800
40. Chang LY, Hsiung CA, Lu CY, Lin TY, Huang FY, Lai YH, et al. Status of cellular rather than humoral immunity is correlated with clinical outcome of enterovirus 71. Pediatric research. 2006;60: 466–471. 16940249
41. Lee MS, Chang LY, Development of enterovirus 71 vaccines. Expert Rev Vaccines. 2010;9: 149–156. doi: 10.1586/erv.09.152 20109026
42. Chiu CH, Chu C, He CC, Lin TY, Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71. Microbes and infection / Institut Pasteur. 2006;8: 1671–1678. 16815726
43. Chen HF, Chang MH, Chiang BL, Jeng ST, Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71. Vaccine. 2006;24: 2944–2951. 16448730
44. Foo DG, Alonso S, Phoon MC, Ramachandran NP, Chow VT, Poh CL, Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res. 2007;125: 61–68. 17222936
45. Quan FS, Huang C, Compans RW, Kang SM, Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol. 2007;81: 3514–3524. 17251294
46. Muir P, Kammerer U, Korn K, Mulders MN, Poyry T, Weissbrich B, et al. Molecular typing of enteroviruses: current status and future requirements. The European Union Concerted Action on Virus Meningitis and Encephalitis. Clinical microbiology reviews. 1998;11: 202–227. 9457433
47. Lin YL, Yu CI, Hu YC, Tsai TJ, Kuo YC, Chi WK, et al. Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles. Vaccine. 2012;30: 1305–1312. doi: 10.1016/j.vaccine.2011.12.081 22214888
48. Denis J, Majeau N, Acosta-Ramirez E, Savard C, Bedard MC, Simard S, et al. Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: evidence for the critical function of multimerization. Virology. 2007;363: 59–68. 17320136
49. Zinkernagel RM, On natural and artificial vaccinations. Annual review of immunology. 2003;21: 515–546. 12500980
50. Gamvrellis A, Leong D, Hanley JC, Xiang SD, Mottram P, Plebanski M, Vaccines that facilitate antigen entry into dendritic cells. Immunology and cell biology. 2004;82: 506–516. 15479436
51. Shao HY, Yu SL, Sia C, Chen Y, Chitra E, Chen IH, et al. Immunogenic properties of RSV-B1 fusion (F) protein gene-encoding recombinant adenoviruses. Vaccine. 2009 DOI: S0264-410X(09)00992-X [pii] doi: 10.1016/j.vaccine.2009.07.004
52. Barouch DH, Nabel GJ, Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Human gene therapy. 2005;16: 149–156. 15761255
53. Evans TG, Bonnez W, Rose RC, Koenig S, Demeter L, Suzich JA, et al. A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J Infect Dis. 2001;183: 1485–1493. 11319684
54. Chang LY, King CC, Hsu KH, Ning HC, Tsao KC, Li CC, et al. Risk factors of enterovirus 71 infection and associated hand, foot, and mouth disease/herpangina in children during an epidemic in Taiwan. Pediatrics. 2002;109: e88. 12042582
55. Chang LY, Tsao KC, Hsia SH, Shih SR, Huang CG, Chan WK, et al. Transmission and clinical features of enterovirus 71 infections in household contacts in Taiwan. JAMA. 2004;291: 222–227. 14722149
56. Yang C, Deng C, Wan J, Zhu L, Leng Q, Neutralizing antibody response in the patients with hand, foot and mouth disease to enterovirus 71 and its clinical implications. Virol J. 2011;8: 306. doi: 10.1186/1743-422X-8-306 21679417
57. Chang LY, Chang IS, Chen WJ, Huang YC, Chen GW, Shih SR, et al. HLA-A33 is associated with susceptibility to enterovirus 71 infection. Pediatrics. 2008;122: 1271–1276. doi: 10.1542/peds.2007-3735 19047245